SEARCH

SEARCH BY CITATION

References

  • 1
    Fleischer B. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J Immunol 1987; 138:134650.
  • 2
    Fleischer B, Sturm E, De-Vries JE, Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988; 141:11037.
  • 3
    Gorrell MD, Wickson J, McCaughan GW. Expression of the rat CD26 antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes. Cell Immunol 1991; 134:20515.
  • 4
    Bühling F & Kunz D et al. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Natural Immunity 1994; 13:2709.
  • 5
    Bühling F & Junker U et al. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995; 45:4751.
  • 6
    Hartel S, Gossrau R, Hanski C, Reutter W. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988; 89:15161.
  • 7
    McCaughan GW, Wickson JE, Creswick PF, Gorrell MD. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990; 11:53444.
  • 8
    Heike M, Mobius U, Knuth A, Meuer S, Meyer-zum-Buschenfelde KH. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol 1988; 74:4314.
  • 9
    Dinjens WN, Ten-Kate J, Van-der-Linden EP, Wijnen JT, Khan PM, Bosman FT. Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. J Histochem Cytochem 1989; 37:186975.
  • 10
    McCaughan GW, Gorrell MD, Bishop GA et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev 2000; 174:17291.
  • 11
    Fox DA, Hussey RE, Fitzgerald KA et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133:12506.
  • 12
    Maes M, De Meester I, Vanhoof G et al. Decreased serum dipeptidyl peptidase IV activity in major depression. Biol Psychiatry 1991; 30:57786.
  • 13
    Abbott CA, Gorrell MD, Kobayashi Y et al. Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration. Int Hepatol Commun 1995; 4:16574.
  • 14
    Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem (Tokyo) 1998; 124:42833.
  • 15
    Durinx C, Lambeir AM, Bosmans E et al. Molecular characterization of dipeptidyl peptidase activity in serum – Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000; 267:560813.DOI: 10.1046/j.1432-1327.2000.01634.x
  • 16
    Bednarczyk JL, Carroll SM, Marin C, McIntyre BW. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991; 46:20618.
  • 17
    Bristol LA, Sakaguchi K, Appella E, Doyle D, Takacs L. Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol 1992; 149:36772.
  • 18
    Dang NH, Torimoto Y, Sugita K et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 1990; 145:396371.
  • 19
    Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990; 144:4092100.
  • 20
    Munoz E, Blazquez MV, Madueno JA, Rubio G, Pena J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 1992; 77:4350.
  • 21
    Schön E, Mansfeld HW, Demuth HU, Barth A, Ansorge S. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta 1985; 44:K915.
  • 22
    Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993; 90:458690.
  • 23
    Hegen M, Mittrucker HW, Hug R et al. Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. Immunobiology 1993; 189:48393.
  • 24
    Reinhold D, Bank U, Bühling F et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 1993; 188:40314.
  • 25
    Morimoto C, Torimoto Y, Levinson G et al. 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 1989; 143:34305.
  • 26
    Gruber M, Scholz W, Flad HD. Influence of human T lymphocytes identified by antibodies to dipeptidyl peptidase IV on differentiation of human B lymphocytes stimulated with Staphylococcus aureus Cowan I and pokeweed mitogen. Cell Immunol 1988; 113:42334.
  • 27
    Morimoto C & Schlossman SF. The structure and function of CD26 in the T cell immune response. Immunol Rev 1998; 161:5570.
  • 28
    Hegen M. CD26 workshop panel report. In: Kishimoto, T, ed. Leucocyte Typing VI. New York: Garland Publishing Inc 1997, 47881.
  • 29
    Tanaka T, Duke-Cohan JS, Kameoka J et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994; 91:30826.
  • 30
    Kenny AJ, Booth AG, George SG et al. Dipeptidyl peptidase IV, a kidney brush border serine protease. Biochem J 1976; 157:16982.
  • 31
    Mentlein R & Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999; 85:924.
  • 32
    Barrett AJ & Rawlings ND. Oligopeptidases, and the emergence of the prolyl oligopeptidase family. Biol Chem Hoppe Seyler 1992; 373:35360.
  • 33
    Barrett AJ, Rawlings ND, Woess JF. Handbook of Proteolytic Enzymes (http://www.merops.co.uk/merops/merops.htm). London. Academic Press 1998, 1666.
  • 34
    Abbott CA, Yu DMT, McCaughan GW, Gorrell MD. Post proline peptidases having DP IV like enzyme activity. Adv Exp Med Biol 2000; 477:1039.
  • 35
    Oravecz T, Pall M, Roderiquez G et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186:186572.
  • 36
    De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today 1999; 20:36775.
  • 37
    De Meester I, Durinx C, Bal G et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 2000; 477: 6788.
  • 38
    Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000; 96:167480.
  • 39
    Ohtsuki T, Tsuda H, Morimoto C. Good or evil: CD26 and HIV infection. J Dermatol Sci 2000; 22:15260.
  • 40
    Valenzuela A, Blanco J, Callebaut C et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol 1997; 158:37219.
  • 41
    Gutheil WG, Subramanyam M, Flentke GR et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994; 91:65948.
  • 42
    Wrenger S, Hoffmann T, Faust J et al. The N-Terminal structure of HIV-1 tat is required for suppression of CD26-dependent T cell growth. J Biol Chem 1997; 272:302838.
  • 43
    De-Pasquale A, Ginaldi L, Limoncelli P, Quaglino D. Dipeptidyl amino peptidase IV cytochemistry in circulating lymphocytes from HIV-I-seropositive subjects. Acta Haematol 1989; 81:1921.
  • 44
    Chalmers AH, Hare C, Woolley G, Frazer IH. Lymphocyte ectoenzyme activity compared in healthy persons and patients seropositive to or at high risk of HIV infection. Immunol Cell Biol 1990; 68:815.
  • 45
    Blazquez MV, Madueno JA, Gonzalez R et al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol 1992; 149:30737.
  • 46
    Vanham G, Kestens L, De Meester I et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993; 6:74957.
  • 47
    Oravecz T, Roderiquez G, Koffi J et al. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-Cell line. Nature Med 1995; 1:91926.
  • 48
    Proost P, De Meester I, Schols D et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998; 273:72227.
  • 49
    Shioda T, Kato H, Ohnishi Y et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998; 95:63316.
  • 50
    Proost P, Struyf S, Schols D et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432:736.
  • 51
    Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993; 177:113543.
  • 52
    Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261:4669.
  • 53
    De Meester I, Vanham G, Kestens L et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994; 24:56670.
  • 54
    Martin M, Huguet J, Centelles JJ, Franco R. Expression of ecto-adenosine deaminase and CD26 in human T Cells triggered by the TCR-CD3 complex – possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995; 155:463043.
  • 55
    Dong RP, Kameoka J, Hegen M et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156:134955.
  • 56
    Dong RP, Tachibana K, Hegen M et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997; 159:60706.
  • 57
    Hegen M, Niedobitek G, Klein CE, Stein H, Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990; 144:290814.
  • 58
    Stein H & Schwarting R et al. Cluster report: CD26. In: KnappW, DorkenB, GilksWR, RieberEP, SchmidtRE, Von SteinH, Dem BorneAEGK, eds. Leucocyte Typing IV. Oxford, UK: Oxford University Press 1989, 4125.
  • 59
    Dinjens. WN, Ten-Kate J, Wijnen JT et al. Distribution of adenosine deaminase-complexing protein in murine tissues. J Biol Chem 1989; 264:1921520.
  • 60
    Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992; 15:104853.
  • 61
    Gossrau R. Histochemical and biochemical distribution of dipeptidyl peptidase IV (DPP IV). Histochemistry 1979; 60:23148.
  • 62
    Marguet D, Bernard AM, Vivier I, Darmoul D, Naquet P, Pierres M. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. J Biol Chem 1992; 267:22008.
  • 63
    Schön E & Ansorge S. Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes. Biol Chem Hoppe Seyler 1990; 371:699705.
  • 64
    Kähne T & Lendeckel U et al. Dipeptidyl peptidase IV. A cell surface peptidase involved in regulating T cell growth. Int J Mol Med 1999; 4:315.
  • 65
    Scholz W, Mentlein R, Heymann E, Feller AC, Ulmer AJ, Flad HD. Interleukin 2 production by human T lymphocytes identified by antibodies to dipeptidyl peptidase IV. Cell Immunol 1985; 93:199211.
  • 66
    Willheim M, Ebner C, Baier K et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones – correlation of CD26 expression with T-H1 subsets. J Allergy Clin Immunol 1997; 100:34855.
  • 67
    Cordero OJ, Salgado FJ, Vinuela JE, Nogueira M. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997; 197:52233.
  • 68
    Dang NH, Torimoto Y, Shimamura K et al. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 1991; 147:282532.
  • 69
    Bristol LA, Finch L, Romm EV, Takacs L. Characterization of a novel rat thymocyte costimulating antigen by the monoclonal antibody 1.3. J Immunol 1992; 148:3328.
  • 70
    Brezinschek RI, Lipsky PE, Galea P, Vita R, Oppenheimermarks N. Phenotypic characterization of CD4 (+) T cells that exhibit a transendothelial migratory capacity. J Immunol 1995; 154:306277.
  • 71
    Hafler DA, Fox DA, Benjamin D, Weiner HL. Antigen reactive memory T cells are defined by Ta1. J Immunol 1986; 137:4148.
  • 72
    De Meester IA, Kestens LL, Vanham GL et al. Costimulation of CD4+ and CD8+ T cells through CD26: the ADA-binding epitope is not essential for complete signaling. J Leukoc Biol 1995; 58:32530.
  • 73
    Falcioni F, Shah H, Vidovic D et al. Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Hum Immunol 1996; 50:7990.
  • 74
    Masuyama J, Yoshio T, Suzuki K et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26 (hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999; 189:97990.
  • 75
    Morimoto C, Lord CI, Zhang C, Duke-Cohan JS, Letvin NL, Schlossman SF. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc Natl Acad Sci USA 1994; 91:99604.
  • 76
    Chambers CA. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9:396404.
  • 77
    Von Bonin A, Hühn J, Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T cell activation pathway. Immunol Rev 1998; 161:4353.
  • 78
    Mattern T, Ansorge S, Flad HD, Ulmer AJ. Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle. Immunobiology 1993; 188:3650.
  • 79
    Dang NH, Hafler DA, Schlossman SF, Breitmeyer JB. FCR-mediated cross linking of Ta1 (CDW26) induced human T cell activation. Cell Immunol 1990; 125:4257.
  • 80
    Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991; 147:25147.
  • 81
    Hegen M, Kameoka J, Dong RP, Schlossman SF, Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997; 90:25764.
  • 82
    Kähne T, Neubert K, Faust J, Ansorge S. Early phosphorylation events induced by DPIV/CD26-specific inhibitors. Cell Immunol 1998; 189:606.DOI: 10.1006/cimm.1998.1355
  • 83
    Flad HD, Gruber M, Scholz W, Feller AC, Ulmer AJ, Heymann E. Phenotypic and functional characterization of human T-lymphocytes defined by monoclonal against dipeptidyl peptidase IV (DPP IV). Adv Biosciences 1987; 65:1925.
  • 84
    Ulmer AJ, Mattern T, Flad HD. Expression of CD26 (dipeptidyl peptidase IV) on memory and naive T lymphocytes. Scand J Immunol 1992; 35:5519.
  • 85
    Plana M, De Vinas O, De-la-Calle-Martin O et al. Induction of interleukin 2 (IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 monoclonal antibody. Eur J Immunol 1991; 21:10858.
  • 86
    Tanaka T, Camerini D, Seed B et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992; 149:4816.
  • 87
    Van der Merwe PA, McNamee PN, Davies EA, Barclay AN, Davis SJ. Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells. Curr Biol 1995; 5:7484.
  • 88
    Kahn-Perles B, Lipcey C, Lecine P, Olive D, Imbert J. Temporal and subunit specific modulation of the Rel/NFkB transcription factors through CD28 costimulation. J Biol Chem 1997; 272:2177483.
  • 89
    Van Gool SW, Vandenberghe P, Boer MD, Cueppens JL. CD80, CD86 and CD40 provide accessory signals in a multi-step T-cell activation model. Immunol Rev 1996; 153:4757.
  • 90
    Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999; 266:798810.DOI: 10.1046/j.1432-1327.1999.00902.x
  • 91
    De Meester I, Vanhoof G, Hendriks D, Demuth HU, Yaron A, Scharpé S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin Chim Acta 1992; 210:2334.
  • 92
    Smith RE, Reynolds CJ, Elder EA. The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV. Histochem J 1992; 24:63747.
  • 93
    Bermpohl F, Loster K, Reutter W, Baum O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. FEBS Lett 1998; 428:1526.
  • 94
    Mittrucker HW, Steeg C, Malissen B, Fleischer B. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol 1995; 25:2957.
  • 95
    Blazquez M, Ortiz C, Aranda E, Collantes E, Israel A, Munoz E. NF-κB activation by CD26 antigen is independent of dipeptidyl peptidase IV activity. Protoplasm 1997; 197:2633.
  • 96
    Augustyns K, Bal G, Thonus G et al. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem 1999; 6:31127.
  • 97
    Hinke SA, Pospisilik JA, Demuth HU et al. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon – Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem 2000; 275:382734.
  • 98
    Wrenger S, Khne T, Bohuon C, Weglohner W, Ansorge S, Reinhold D. Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett 2000; 466:1559.
  • 99
    Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. A guardian angel. the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci 2000; 99:93104.
  • 100
    Lambeir A-M, Proost P, Durinx C et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276 :in press.
  • 101
    Subramanyam M, Gutheil WG, Bachovchin WW, Huber BT. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993; 150:254453.
  • 102
    Marguet D, Baggio L, Kobayashi T et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97:68749.
  • 103
    Iwata S, Yamaguchi N, Munakata Y et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES. possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999; 11:41726.
  • 104
    Schön E, Jahn S, Kiessig ST et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987; 17:18216.
  • 105
    Ansorge S & Schön E. Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system. Acta Histochem 1987; 82:416.
  • 106
    Ansorge S, Schön E, Kunz D. Membrane-bound peptidases of lymphocytes: functional implications. Biomed Biochim Acta 1991; 50:799807.
  • 107
    Reinhold D, Bank U, Bühling F et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 1994; 192:12136.
  • 108
    Reinhold D, Ansorge S, Grungreiff K. Zinc regulates DNA synthesis and IL-2, IL-6, and IL-10 production of PWM-stimulated PBMC and normalizes the peripheral cytokine concentration in chronic liver disease. J Trace Elements Exp Medicine 1997; 10:1927.
  • 109
    Hegen M, Camerini D, Fleischer B. Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. Cell Immunol 1993; 146:24960.DOI: 10.1006/cimm.1993.1024
  • 110
    Coburn MC, Hixson DC, Reichner JS. In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV. Cell Immunol 1994; 158:26980.DOI: 10.1006/cimm.1994.1275
  • 111
    Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997; 19:1524.
  • 112
    Steeg C, Hartwig U, Fleischer B. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell Immunol 1995; 164:3115.DOI: 10.1006/cimm.1995.1175
  • 113
    Hühn J, Ehrlich S, Fleischer B, Von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 2000; 72:12732.
  • 114
    Schrader WP, West CA, Miczek AD, Norton EK. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. J Biol Chem 1990; 265:193128.
  • 115
    Ruers TJ, Buurman WA, Van Der Linden CJ. 2′Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells. J Immunol 1987; 138:11622.
  • 116
    Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998; 161:2742.
  • 117
    Van der Weyden MB & Kelley WN. Adenosine deaminase and immune function. Br J Haematol 1976; 34:15965.
  • 118
    Hovi T, Smyth JF, Allison AC, Williams SC. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol 1976; 23:395403.
  • 119
    Carson DA & Seegmiller JE. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J Clin Invest 1976; 57:27482.
  • 120
    Migchielsen AA, Breuer ML, Van Roon MA et al. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 1995; 10:27987.
  • 121
    Wakamiya M, Blackburn MR, Jurecic R et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 1995; 92:36737.
  • 122
    Bollinger ME, Arredondovega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996; 334:136771.
  • 123
    Daddona PE & Kelley WN. Human adenosine deaminase binding protein. Assay, purification, and properties. J Biol Chem 1978; 253:461723.
  • 124
    Aran JM, Colomer D, Matutes E, Vives-Corrons JL, Franco R. Presence of adenosine deaminase on the surface of mononuclear blood cells: immunochemical localization using light and electron microscopy. J Histochem Cytochem 1991; 39:10018.
  • 125
    Dinjens WN, Van-der-Boon J, Ten-Kate J, Zeijlemaker WP, De-Bruijn CH, Bosman FT, Khan PM. Cell surface adenosine deaminase (ADA) and its complexing protein (ADCP) in human T-lymphoid cells. Adv Exp Med Biol 1986; 195:40714.
  • 126
    Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291:130451.DOI: 10.1126/science.1058040
  • 127
    Iwaki-Egawa S, Watanabe Y, Fujimoto Y. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. Cell Immunol 1997; 178:1806.DOI: 10.1006/cimm.1997.1123
  • 128
    Ben-Shooshan I & Parola AH. The CP-I subunit of adenosine deaminase complexing protein from calf kidney is identical to human, mouse and rat dipeptidyl peptidase IV. Comp Biochem Physiol B Biochem Mol Biol 1998; 119:28992.
  • 129
    Franco R, Casado V, Ciruela F et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997; 52:28394.
  • 130
    Zimmerman H. Extracellular purine metabolism. Drug Dev Res 1996; 39:33752.
  • 131
    Resta R, Yamashita Y, Thompson L. Ecto-enyzme and signaling functions of lymphocytes CD73. Immunol Rev 1998; 161:95109.
  • 132
    Lund FE, Cockayne DA, Randall TD, Solvason N, Schuber F, Howard MC. CD38: a new paradigm in lymphocyte activation and signal transduction. Immunol Rev 1998; 161:7993.
  • 133
    Torimoto Y, Dang NH, Tanaka T, Prado C, Schlossman SF, Morimoto C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol Immunol 1992; 29:18392.
  • 134
    Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV. The Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency. J Exp Med 2000; 192:122335.
  • 135
    Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J Exp Med 1990; 172:64952.
  • 136
    Hanski C, Huhle T, Reutter W. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 1985; 366:116976.
  • 137
    Piazza GA, Callanan HM, Mowery J, Hixson DC. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem J 1989; 262:32734.
  • 138
    Fülop V & Jones DT. Beta propellers. structural rigidity and functional diversity. Curr Opinion Struc Biol 1999; 9:71521.
  • 139
    Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell Biol 2000; 10:1724.
  • 140
    Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 1998; 273:2420715.
  • 141
    Gonzalez-Gronow M, Weber MR, Gawdi G, Pizzo SV. Dipeptidyl peptidase IV (CD26) is a receptor for streptokinase on rheumatoid synovial fibroblasts. Fibrinol Proteol 1998; 12:12935.
  • 142
    Loster K, Zeilinger K, Schuppan D, Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD26) is the collagen-binding site. Biochem Biophys Res Commun 1995; 217:3418.DOI: 10.1006/bbrc.1995.2782
  • 143
    Werkmeister JA & Ramshaw JA. Multiple antigenic determinants on type III collagen. Biochem J 1991; 274:8958.
  • 144
    Abbott CA, Gorrell MD, Levy MT, McCaughan GW. Molecular analyses of human and rat dipeptidyl peptidase IV. Adv Exp Med Biol 1997; 421:16170.
  • 145
    Mueller SC, Ghersi G, Akiyama SK et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem 1999 2001; 274:2494752.
  • 146
    McPherson JD, Marra M, Hillier L et al. A physical map of the human genome (http://genome.ucsc.edu/). Nature 2001; 409:93441.DOI: 10.1038/35057157
  • 147
    Levy MT, McCaughan GW, Abbott CA et al. Fibroblast activation protein. A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29:176878.
  • 148
    Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267:614050.DOI: 10.1046/j.1432-1327.2000.01617.x
  • 149
    Trugnan G, Ait-Slimane T, David F et al. Dipeptidyl peptidase IV (DPPIV/CD26): biochemistry and control of cell-surface expression. In: Kenny, AJ Boustead, CM, eds. Cell-Surface Peptidases in Health and Disease. Oxford: BIOS Scientific Publishers 1997, 20317.
  • 150
    Abbott CA, McCaughan GW, Gorrell MD. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett 1999; 458:27884.
  • 151
    Fülop V, Szeltner Z, Polgar L. Catalysis of serine oligopeptidases is controlled by a gating filter mechanism. EMBO Reports 2000; 1:27781.DOI: 10.1093/embo-reports/kvd048
  • 152
    Gorrell MD, Abbott CA, Kähne T, Levy MT, Church WB, McCaughan GW. Relating structure to function in the beta-propeller domain of dipeptidyl peptidase IV. Point mutations that ablate adenosine deaminase binding, antibody binding or DPP IV enzyme activity. Adv Exp Med Biol 2000; 477:8995.
  • 153
    Springer TA. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci USA 1997; 94:6572.
  • 154
    Fülop V, Bocskei Z, Polgar L. Prolyl oligopeptidase – an unusual beta-propeller domain regulates proteolysis. Cell 1998; 94:16170.
  • 155
    Krepela E, Kraml J, Vicar J, Kadlecova L, Kasafirek E. Demonstration of two molecular forms of dipeptidyl peptidase IV in normal human serum. Physiol Bohemoslov 1983; 32:48696.
  • 156
    Kähne T & Kroning H et al. Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Cell Immunol 1996; 170:6370.DOI: 10.1006/cimm.1996.0134
  • 157
    Misumi Y, Hayashi Y, Arakawa F, Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1992 1995; 1131:3336.
  • 158
    Marguet D, Bernard A, David F, Lazaro-Trueba I, Pierres M. Structural organization of the DP IV gene and its relationship with DPX and FAP-alpha transcripts. In: Fleischer, B, ed. Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response. Georgetown, Texas: R.G. Landes Company, 3753.
  • 159
    Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organisation, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994; 40:3318.
  • 160
    Hong WJ & Doyle D. Molecular dissection of the NH2-terminal signal/anchor sequence of rat dipeptidyl peptidase IV. J Cell Biol 1990; 111:3238.
  • 161
    Ogata S, Misumi Y, Ikehara Y. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem 1989; 264:3596601.
  • 162
    David F, Bernard AM, Pierres M, Marguet D. Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases. J Biol Chem 1993; 268:1724752.
  • 163
    Gorrell MD, Levy MT, Abbott CA, Washington EA, McCaughan GW. CD26. Adenosine deaminase binding, immunoblotting and species cross reactivity examined using recombinant proteins. In: Kishimoto, T, ed. Leucocyte Typing VI. New York: Garland Publishing Inc 1997, 4845.
  • 164
    Dong RP, Tachibana K, Hegen M et al. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. Mol Immunol 1998; 35:1321.
  • 165
    Hühn J, Olek S, Fleischer B, Von Bonin A. The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV (CD26) molecule. Cell Immunol 1999; 192:3340.DOI: 10.1006/cimm.1998.1436
  • 166
    Jones S & Thornton J. Principles of protein–protein interactions. Proc Natl Acad Sci USA 1996; 93:1320.
  • 167
    Lambeir AM, Pereira JFD, Chacon P et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. BBA – Prot Stru Mol Enzymol 1997; 1340:21526.
  • 168
    Scanlan MJ, Raj BK, Calvo B et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994; 91:565761.
  • 169
    Nagatsu T, Hino M, Fuyamada H. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem 1976; 74:46676.
  • 170
    Hino M, Fuyamada H, Hayakawa T, Nagatsu T, Oya H. X-prolyl dipeptidyl-aminopeptidase activity, with x-proline p-nitroanilides as substrates, in normal and pathological human sera. Clin Chem 1976; 22:125661.
  • 171
    Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidyl peptidase IV found in human serum – isolation, characterization, and comparison with T lymphocyte membrane dipeptidyl peptidase IV (CD26). J Biol Chem 1995; 270:1410714.
  • 172
    Fukasawa KM, Fukasawa K, Hiraoka BY, Harada M. Characterization of a soluble form of dipeptidyl peptidase IV from pig liver. Experientia 1983; 39:10057.
  • 173
    Danielsen EM, Sjostrom H, Noren O. Biosynthesis of intestinal microvillar proteins. Pulse-chase labelling studies on maltase-glucoamylase, aminopeptidase A and dipeptidyl peptidase IV. Biochem J 1983; 210:38993.
  • 174
    Walter R, Simmons WH, Yoshimoto T. Proline specific endo- and exopeptidases. Mol Cell Bioc 1980; 30:11127.
  • 175
    Seidl R, Mann K, Schafer W. N-terminal amino-acid sequence of pig kidney dipeptidyl peptidase IV solubilized by autolysis. Biol Chem Hoppe Seyler 1991; 372:2134.
  • 176
    Macnair DC & Kenny AJ. Proteins of the kidney microvillar membrane: The amphipathic form of dipeptidyl peptidase iv. Biochem J 1979; 179:37995.
  • 177
    Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136:358596.
  • 178
    Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD. Antibody-induced modulation of CD26 surface expression. Immunology 1995; 84:595600.
  • 179
    Teague TK, Hildeman D, Kedl RM et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci USA 1999; 96:126916.
  • 180
    Bulera SJ, Eddy SM, Ferguson E et al. RNA expression in the early characterization of hepatotoxicants in wistar rats by high-density DNA microarrays. Hepatology 2001; 33:123958.DOI: 10.1053/jhep.2001.23560
  • 181
    Rogge L, Bianchi E, Biffi M et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000; 25:9610.DOI: 10.1038/75671
  • 182
    Danielsen EM, Cowell GM, Poulsen SS. Biosynthesis of intestinal microvillar proteins. Role of the Golgi complex and microtubules. Biochem J 1983; 216:3742.
  • 183
    Hong WJ, Piazza GA, Hixson DC, Doyle D. Expression of enzymatically active rat dipeptidyl peptidase IV in Chinese hamster ovary cells after transfection. Biochemistry 1989; 28:84749.
  • 184
    Urade M, Uematsu T, Mima T, Ogura T, Matsuya T. Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene. J Oral Pathol Med 1992; 21:10912.
  • 185
    Fujita K, Hirano M, Tokunaga K, Nagatsu I, Nagatsu T, Sakakibara S. Serum glycylproline p-nitroanilidase activity in blood cancers. Clin Chim Acta 1977; 81:2157.
  • 186
    Fukasawa K, Harada M, Komatsu M et al. Serum dipeptidyl peptidase (DPP) IV activities in oral cancer patients. Int J Oral Surg 1982; 11:24650.
  • 187
    Haacke W, Kullertz G, Barth A. Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers. Arch Geschwulstforch 1986; 56:14553.
  • 188
    Hanski C, Zimmer T, Gossrau R, Reutter W. Increased activity of dipeptidyl peptidase IV in serum of hepatoma-bearing rats coincides with the loss of the enzyme from the hepatoma plasma membrane. Experientia 1986; 42:8268.
  • 189
    Ivanov S, Kolinska J, Kraml J, Chelibonova-Lorer H. Gamma-Glutamyltranspeptidase and dipeptidyl peptidase IV activity in the serum of normal and hepatoma-bearing chickens and in the plasma membranes from liver and hepatoma MC-29. Cancer Biochem Biophys 1992; 13:439.
  • 190
    Korom S, De Meester I, Onodera K et al. The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. Transplant Proc 1997; 29:12745.
  • 191
    Kubota T, Iizuka H, Bachovchin WW, Stollar BD. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol 1994; 96:2926.
  • 192
    Steinbrecher A, Reinhold D, Quigley L et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 2001; 166:20418.
  • 193
    Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T. Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients. Clin Chem 1988; 34:2499501.
  • 194
    Maes M, De Meester I, Verkerk R et al. Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression – relationships with immune-inflammatory markers. Psychoneuroendocrinology 1997; 22:6578.DOI: 10.1016/S0306-4530(96)00040-6
  • 195
    Fujita K, Hagihara M, Nagatsu T, Iwata H, Miura T. The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen. Biochem Med Metab Biol 1992; 48:22734.
  • 196
    Hagihara M, Ohhashi M, Nagatsu T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin Chem 1987; 33:14635.
  • 197
    Kullertz G & Boigk J. Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis. Zrheumatol 1986; 45:526.
  • 198
    Stancikova M, Lojda Z, Lukac J, Ruzickova M. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1992; 10:3815.
  • 199
    Murray JL, Loftin KC, Munn CG, Reuben JM, Mansell PW, Hersh EM. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome. Blood 1985; 65:131824.
  • 200
    Van West D, Monteleone P, Di Lieto A et al. Lowered Serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa. European Arch Psychiatry Clin Neuroscience 2000; 250:8692.
  • 201
    Krepela E, Kasafirek E, Vicar J, Kraml J. An assay of dipeptidyl peptidase IV activity in human serum and serum of pregnant women with glycyl-l-proline-1-naphthylamide and other glycyl-l-proline-arylamides as substrates. Physiol Bohemoslov 1983; 32:33445.
  • 202
    Schmitz T, Underwood R, Khiroya R, Bachovchin WW, Huber BT. Potentiation of the immune response in HIV-1 (+) individuals. J Clin Invest 1996; 97:15459.
  • 203
    Hartmann B, Harr MB, Jeppesen PB et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metabolism 2000; 85:28848.
  • 204
    O'Harte FPM, Mooney MH, Kelly CMN, McKillop AM, Flatt PR. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7–36)amide in obese diabetic ob/ob mice. Regul Pept 2001; 96:95104.
  • 205
    Pospisilik JA, Hinke SA, Pederson RA et al. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept 2001; 96:13341.
  • 206
    Struyf S, Proost P, Sozzani S et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 1998; 161:26725.
  • 207
    Proost P, Struyf S, Couvreur M et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2 (6–76) as a natural chemokine inhibitor. J Immunol 1998; 160:403441.
  • 208
    Struyf S, Proost P, Schols D et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999; 162:49039.
  • 209
    Proost P, Struyf S, Schols D et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999; 274:398893.
  • 210
    Van Coillie E, Proost P, Van Aelst I et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998; 37:1267280.DOI: 10.1021/bi980497d
  • 211
    Scheel-Toellner D, Richter E, Toellner KM et al. CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma. Lab Invest 1995; 73:68590.